SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock investors bought 38,662 call options on the company. This is an increase of 44% compared to the average volume of 26,826 call options.
Hedge Funds Weigh In On SELLAS Life Sciences Group
Hedge funds have recently bought and sold shares of the company. Dagco Inc. bought a new position in SELLAS Life Sciences Group in the 4th quarter valued at about $2,177,000. Everhart Financial Group Inc. bought a new position in SELLAS Life Sciences Group in the 3rd quarter valued at about $533,000. Anson Funds Management LP increased its holdings in SELLAS Life Sciences Group by 2,093.8% in the 3rd quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock valued at $9,713,000 after buying an additional 5,757,938 shares during the period. Trustmark Bank Trust Department bought a new position in SELLAS Life Sciences Group in the 3rd quarter valued at about $59,000. Finally, Axxcess Wealth Management LLC bought a new position in SELLAS Life Sciences Group in the 3rd quarter valued at about $26,000. 17.38% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
SLS has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. Maxim Group upped their price objective on SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 12th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.
SELLAS Life Sciences Group Trading Up 23.6%
NASDAQ SLS traded up $1.23 during trading on Wednesday, reaching $6.45. The company’s stock had a trading volume of 21,932,639 shares, compared to its average volume of 7,401,779. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -25.86 and a beta of 2.24. SELLAS Life Sciences Group has a 12 month low of $1.39 and a 12 month high of $6.72. The firm has a 50 day moving average price of $4.95 and a 200 day moving average price of $3.64.
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.
The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.
Read More
- Five stocks we like better than SELLAS Life Sciences Group
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
- 3 Sectors That Look Most Vulnerable Ahead of May 15
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
